1. A phase I randomized controlled trial to evaluate safety and clinical effect of topically applied GSK2981278 ointment in a psoriasis plaque test. (1st June 2018) Authors: Kang, E.G.; Wu, S.; Gupta, A.; von Mackensen, Y.‐L.; Siemetzki, H.; Freudenberg, J.M.; Wigger‐Alberti, W.; Yamaguchi, Y. Journal: British journal of dermatology Issue: Volume 178:Number 6(2018) Page Start: 1427 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase I randomized controlled trial to evaluate safety and clinical effect of topically applied GSK2981278 ointment in a psoriasis plaque test. (23rd March 2018) Authors: Kang, E.G.; Wu, S.; Gupta, A.; von Mackensen, Y.‐L.; Siemetzki, H.; Freudenberg, J.M.; Wigger‐Alberti, W.; Yamaguchi, Y. Journal: British journal of dermatology Issue: Volume 178:Number 6(2018) Page Start: 1427 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A phase I randomized trial to assess the effect on skin infiltrate thickness and tolerability of topical phosphodiesterase inhibitors in the treatment of psoriasis vulgaris using a modified psoriasis plaque test. (8th August 2016) Authors: Snape, S.D.; Wigger‐Alberti, W.; Goehring, U.M. Journal: British journal of dermatology Issue: Volume 175:Number 3(2016) Page Start: 479 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A phase I randomized trial to assess the effect on skin infiltrate thickness and tolerability of topical phosphodiesterase inhibitors in the treatment of psoriasis vulgaris using a modified psoriasis plaque test. (1st September 2016) Authors: Snape, S.D.; Wigger‐Alberti, W.; Goehring, U.M. Journal: British journal of dermatology Issue: Volume 175:Number 3(2016) Page Start: 479 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A phase I, randomized, double‐blind study to assess the safety, tolerability and efficacy of the topical RORC2 inverse agonist PF‐06763809 in participants with mild‐to‐moderate plaque psoriasis. (14th September 2020) Authors: Berstein, G.; Zhang, Y.; Berger, Z.; Kieras, E.; Li, G.; Samuel, A.; Yeoh, T.; Dowty, H.; Beaumont, K.; Wigger‐Alberti, W.; von Mackensen, Y.; Kroencke, U.; Hamscho, R.; Garcet, S.; Krueger, J. G.; Banfield, C.; Oemar, B. Journal: Clinical and experimental dermatology Issue: Volume 46:Number 1(2021) Page Start: 122 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. A phase I, randomized, double‐blind study to assess the safety, tolerability and efficacy of the topical RORC2 inverse agonist PF‐06763809 in participants with mild‐to‐moderate plaque psoriasis. (1st January 2021) Authors: Berstein, G.; Zhang, Y.; Berger, Z.; Kieras, E.; Li, G.; Samuel, A.; Yeoh, T.; Dowty, H.; Beaumont, K.; Wigger‐Alberti, W.; von Mackensen, Y.; Kroencke, U.; Hamscho, R.; Garcet, S.; Krueger, J. G.; Banfield, C.; Oemar, B. Journal: Clinical and experimental dermatology Issue: Volume 46:Number 1(2021) Page Start: 122 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Adapting epicutaneous patch testing protocols to assess immediate‐type skin reactions. (25th June 2020) Authors: Mehling, A.; Benard, S.; Braun, N.; Degwert, J.; Duttine, M.; Jassoy, C.; Merk, H.; Rossow, U.; Welzel, J.; Wigger‐Alberti, W.; Wilhelm, K.P.; Ennen, J. Journal: International journal of cosmetic science Issue: Volume 42:Number 4(2020) Page Start: 328 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗